Author:
Loizaga-Iriarte A.,Lacasa-Viscasillas I.,Senarriaga-Ruiz de la Illa N.,Unda-Urzaiz M.,Rodriguez-Antolin A.,Miñana-Lopez B.,Cozar-Olmo J.M.
Reference14 articles.
1. NCCN Clinical practice guidelines in oncology: Prostate cancer. Version 2.2016. [consulted 10 Apr 2016]. Available from: www.nccn.org
2. EAU Guidelines 2016. [consulted 10 Apr 2016]. Available from: http://uroweb.org/guideline/prostate-cancer/
3. AUA castration-resistant prostate cancer guideline. [consulted 10 Apr 2016]. Available from: http://www.auanet.org/education/guidelines/castration-resistant-prostate-cancer.cfm
4. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis;Shen;Skeletal Radiol,2014
5. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind,